RT Journal Article
SR Electronic
T1 Coding Long COVID: Characterizing a new disease through an ICD-10 lens
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.18.22273968
DO 10.1101/2022.04.18.22273968
A1 Emily R Pfaff
A1 Charisse Madlock-Brown
A1 John M. Baratta
A1 Abhishek Bhatia
A1 Hannah Davis
A1 Andrew Girvin
A1 Elaine Hill
A1 Liz Kelly
A1 Kristin Kostka
A1 Johanna Loomba
A1 Julie A. McMurry
A1 Rachel Wong
A1 Tellen D Bennett
A1 Richard Moffitt
A1 Christopher G Chute
A1 Melissa Haendel
A1 The N3C Consortium
A1 The RECOVER Consortium
YR 2022
UL http://medrxiv.org/content/early/2022/04/19/2022.04.18.22273968.abstract
AB Naming a newly discovered disease is always challenging; in the context of the COVID-19 pandemic and the existence of post-acute sequelae of SARS-CoV-2 infection (PASC), which includes Long COVID, it has proven especially challenging. Disease definitions and assignment of a diagnosis code are often asynchronous and iterative. The clinical definition and our understanding of the underlying mechanisms of Long COVID are still in flux. The deployment of an ICD-10-CM code for Long COVID in the US took nearly two years after patients had begun to describe their condition. Here we leverage the largest publicly available HIPAA-limited dataset about patients with COVID-19 in the US to examine the heterogeneity of adoption and use of U09.9, the ICD-10-CM code for “Post COVID-19 condition, unspecified.”Our results include a characterization of common diagnostics, treatment-oriented procedures, and medications associated with U09.9-coded patients, which give us insight into current practice patterns around Long COVID. We also established the diagnoses most commonly co-occurring with U09.9, and algorithmically clustered them into three major categories: cardiopulmonary, neurological, and metabolic. We aim to apply the patterns gleaned from this analysis to flag probable Long COVID cases occurring prior to the existence of U09.9, thus establishing a mechanism to ensure patients with earlier cases of Long-COVID are no less ascertainable for current and future research and treatment opportunities.Competing Interest StatementAT Girvin is an employee of Palantir Technologies. MA Haendel and JA McMurry are co-founders of Pryzm Health.Funding StatementThis research was funded by the National Institutes of Health (NIH) Agreement OT2HL161847-01. The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the NIH. All authors are funded under this mechanism. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRBs of the University of North Carolina at Chapel Hill, University of Tennessee Health Science Center, University of Rochester, Northeastern University, University of Virginia, University of Colorado, Stony Brook University, and Johns Hopkins University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol # IRB00249128 or individual site agreements with NIH. The N3C Data Enclave is managed under the authority of the NIH; information can be found at ncats.nih.gov/n3c/resources. Enclave data is protected, and can be accessed for COVID-related research with an approved (1) IRB protocol and (2) Data Use Request (DUR). Enclave and data access instructions can be found at https://covid.cd2h.org/for-researchers; all code used to produce the analyses in this manuscript is available within the N3C Enclave to users with valid login credentials to support reproducibility.